Intraoperative electron radiation therapy

Last updated
Intraoperative electron radiation therapy
Other namesIOERT
ICD-9-CM 92.41

Intraoperative electron radiation therapy is the application of electron radiation directly to the residual tumor or tumor bed during cancer surgery. [1] [2] Electron beams are useful for intraoperative radiation treatment because, depending on the electron energy, the dose falls off rapidly behind the target site, therefore sparing underlying healthy tissue.

Contents

IOERT has been called "precision radiotherapy," because the physician has direct visualization of the tumor and can exclude normal tissue from the field while protecting critical structures within the field and underlying the target volume. One advantage of IOERT is that it can be given at the time of surgery when microscopic residual tumor cells are most vulnerable to destruction. Also, IOERT is often used in combination with external beam radiotherapy (EBR) because it results in less integral doses and shorter treatment times.

Medical uses

IOERT has a long history of clinical applications, with promising results, in the management of solid tumors (e.g., pancreatic cancer, locally advanced and recurrent rectal cancer, breast tumors, sarcomas, and selected gynaecologic and genitourinary malignancies, neuroblastomas [3] and brain tumors. [4] In virtually every tumor site, electron IORT improves local control, reducing the need for additional surgeries or interventions. The following is a list of disease sites currently treated by IOERT:

Breast cancer

Since 1975, breast cancer rates have declined in the U.S., largely due to mammograms and the use of adjuvant treatments such as radiotherapy. Local recurrence rates are greatly reduced by postoperative radiotherapy, which translates into improved survival: Preventing four local recurrences can prevent one breast cancer death. In one of the largest published studies so far called (ELIOT), [5] researchers found that after treating 574 patients with full-dose IOERT with 21  Gy, at a median follow-up of 20 months, there was an in-breast tumor recurrence rate of only 1.05%. [6] Other studies show that IOERT provides acceptable results when treating breast cancer in low-risk patients. More research is needed for defining the optimal dose of IOERT, alone or in combination with EBRT, and for determining when it may be appropriate to use it as part of the treatment for higher risk patients. [7]

Colorectal cancer

Over the past 30 years, treatment of locally advanced colorectal cancer has evolved, particularly in the area of local control – stopping the spread of cancer from the tumor site. IOERT shows promising results. When combined with preoperative external beam irradiation plus chemotherapy and maximal surgical resection, it may be a successful component in the treatment of high-risk patients with locally advanced primary or locally recurrent cancers. [8]

Gynecological cancer

Studies suggest that electron IORT may play an important and useful role in the treatment of patients with locally advanced and recurrent gynecologic cancers, especially for patients with locally recurrent cancer after treatment for their primary lesion. Further research into radiation doses and how to best combine IOERT with other interventions will help to define the sequencing of treatment and the patients who would most benefit from receiving electron IORT, as part of the multimodality treatment of this disease. [9]

Head and neck cancer

Head and neck cancers are often difficult to treat and have a high rate of recurrence or metastasis. IOERT is an effective means of treating locally advanced or recurrent head and neck cancers. Furthermore, research shows that a boost given by IOERT reduces the ability for surviving tumor cells to replicate, creating extra time for healing of the surgical wound before EBRT is administered. [10] [11]

Pancreatic cancer

In the U.S., pancreatic cancer is the fourth leading cause of cancer death, even though there has been a slight improvement in mortality rates in recent years. Although the optimal treatment plan remains debated, a combination of radiotherapy and chemotherapy is favored in the U.S. [12] As part of a multimodality treatment, IOERT appears to reduce local recurrence when combined with EBRT, chemoradiation, and surgical resection. [13]

Soft tissue sarcomas

Soft tissue sarcomas can be effectively treated by electron IORT, which appears to be gaining acceptance as the current practice for sarcomas in combination with EBRT (preferably preoperative) and maximal resection. Used together, IOERT and EBRT appear to be improving local control, and this method is being refined so that it can effectively be used in combination with other interventions if indicated. In studies regarding the delivery of therapeutic radiation in the limb-sparing approach to extremity soft tissue sarcomas, electron IORT has been called ‘precision radiotherapy’ by some, because the treating physician has direct visualization of the tumor or surgical cavity and can manually exclude normal tissue from the field. [14] [15]

History

Spanish [16] and German doctors, [17] in 1905 and 1915 respectively, used intraoperative radiation therapy (IORT) in an attempt to eradicate residual tumors left behind after surgical resection. However, radiation equipment in the early twentieth-century could only deliver low energy X-rays, which had relatively poor penetration; high doses of radiation could not be applied externally without doing unacceptable damage to normal tissues. IORT treatments with low energy or "orthovoltage" X-rays gained advocates throughout the 1930s and 1940s, but the results were inconsistent. The X-rays penetrated beyond the tumor bed to the normal tissues beneath, had poor dose distributions, and took a relatively long time to administer. The technique was largely abandoned in the late 1950s with the advent of megavoltage radiation equipment, which enabled the delivery of more penetrating external radiation. [18]

In 1965, the modern era of IOERT began in Japan at Kyoto University where patients were treated with electrons generated by a betatron [19] Compared with other forms of IORT such as orthovoltage X-ray beams, electron beams improved IOERT dose distributions, limited penetration beyond the tumor, and delivered the required dose much more rapidly. Normal tissue beneath the tumor bed could be protected and shielded, if required, and the treatment took only a few minutes to deliver. These advantages made electrons the preferred radiation for IOERT. The technique gained favor in Japan. Other Japanese hospitals initiated IOERT using electron beams, principally generated from linear particle accelerators. At most institutions, patients were operated on in the operating room (OR) and were transported to the radiation facility for treatment.

With the Japanese IOERT technique, relatively large single doses of radiation were administered during surgery, and most patients received no follow-up external radiation treatment. Even though this reduced the overall dose that could potentially be delivered to the tumor site, the early Japanese results were impressive, particularly for gastric cancer. [20]

The Japanese experience was encouraging enough for several U.S. centers to institute IOERT programs. The first one began at Howard University in 1976 [21] and followed the Japanese protocol of a large, single dose. Howard built a standard radiation therapy facility with one room that could be used as an OR as well as for conventional treatment. Because the radiation equipment was also used for conventional therapy, the competition for the machine limited the number of patients that could be scheduled for IOERT.

In 1978, Massachusetts General Hospital (MGH) started an IORT program. [22] The MGH doctors scheduled one of their conventional therapy rooms for IOERT one afternoon a week, performed surgery in the OR, and transported the patient to the radiation therapy room during surgery. This used the radiation equipment more efficiently and required no additional capital outlay. However, about 30-50% of the patients planned for IOERT were found to be unsuitable candidates for IORT at the time of surgery, mainly because the disease had spread to adjacent organs. This factor, combined with the risks and complexities of moving a patient during surgery, severely limited the number of patients who could be treated using the MGH method of IOERT. Consequently, conventional fractionated external beam irradiation was added to the IOERT dose, either prior to or subsequent to the surgery, in the MGH IOERT program.

The National Cancer Institute (NCI) started an IOERT program in 1979. [23] [24] [25] Their approach combined maximal surgical resection and IOERT and, in most cases, did not include conventional external beam therapy as part of the treatment. Because the NCI protocol relied on IOERT radiation alone, the IOERT fields were often very large, sometimes requiring two or three adjacent and overlapping fields to cover the tumor site. While the NCI results for these very large tumors were not encouraging, they showed that even the combination of aggressive surgery and large IOERT fields had acceptable toxicity. Furthermore, they introduced several technical innovations to IOERT, including the use of television for simultaneous periscopic viewing of the tumor by the surgical team.

In 1981 the Mayo Clinic tried yet another arrangement. [26] They built an OR adjacent to the radiation therapy department. Potential IOERT patients underwent surgery in the regular OR suite. If they were found to be candidates for IOERT, a second surgical procedure was scheduled in the OR adjacent to the radiation facility. By scheduling only those patients known to be suitable for IOERT, they made more efficient use of their radiation therapy machine, but at the cost of subjecting patients to a second surgery. Subsequently, the Mayo Clinic remodeled an OR and installed a conventional radiation therapy machine with its required massive shield walls, and the clinic now routinely treats over 100 IORT patients per year. After 1985, Siemens Medical Systems offered a specialized LINAC for IOERT. It was designed to be used in the OR, but it weighed more than eight tons and required about 100 tons of shielding. This proved to be too expensive an approach for the medical community, and only seven of these specialized units were ever sold.

Dedicating an OR to IOERT increases the number of patients that can be treated and eliminates the risks of double surgeries and moving a patient during surgery. It also eliminates the complex logistics involved in moving patients from the OR to the therapy room and back to the OR. However, this solution has its own disadvantages: Remodeling an OR and purchasing an accelerator is expensive. Moreover, IORT is restricted to that one, specialized OR. Even so, the Mayo Clinic model demonstrated that when therapy equipment is located within an OR, the number of IOERT procedures will increase. In 1985, IOERT began in Italy and involved a specialized method to facilitate surgery followed by transport to the radiotherapy treatment room. Around the same time in France, another IOERT method was developed using the Lyon intra-operative device. [27] [28] [29]

In 1982 the Joint Center for Radiation Therapy (JCRT), [30] at Harvard Medical School, attempted to reduce the cost of performing IORT in an OR by using orthovoltage X-rays to provide the intraoperative dose, which was similar to the approach used in Germany in 1915. But this was less than ideal. While the shielding costs and the cost and weight of the equipment compared favorably with conventional electron accelerators, dose distributions were inferior; treatment times were longer; and bones received a higher radiation dose. For these reasons, the centers rejected IO orthovoltage (X-rays) radiation therapy machines. In addition, these orthovoltage machines (300 kvp) were not designed to be mobile.

Advent of Portable Linear Accelerators

In the 1990s, electron IORT experienced resurgence, due to the development of mobile linear accelerators that used electron beams—the Mobetron, LIAC, and NOVAC-7 -- and the increasing use of IOERT to treat breast cancer. [31] Prior to the invention of portable LINACs for IOERT, clinicians could only treat IORT patients in specially shielded operating rooms, which were expensive to build, or in a radiotherapy room, which required transporting the anesthetized patient from the OR to the LINAC for treatment. [32] These factors were major obstructions to the widespread adoption of IORT because they added significant cost to treatment as well as logistical complications to surgery, including an increased risk of infection to the patient.

Because portable LINACs for IOERT produced electron beams of energy less than or equal to 12  MeV and did not use bending magnets, the secondary radiation emitted was so low that it didn’t require permanent shielding in the operating room. This greatly reduced the cost of either constructing a new OR or retrofitting an old one. [31] By using mobile units, the possibility of treating patients with IORT was no longer restricted to the availability of special shielded operating rooms, but could be done in regular unshielded ORs.

Currently, the Mobetron, LIAC, and NOVAC-7 linear accelerators are improving patient care by delivering intraoperative radiation electron beam therapy to cancer patients during surgery. All three units are compact and mobile. Invented in the U.S. in 1997, the Mobetron uses X-band technology and a soft docking system. The LIAC and NOVAC-7 are robotic devices developed in Italy that use S-band technology and a hard-docking system. The NOVAC-7 became available for clinical use in the 1990s while the LIAC was introduced to a clinical environment in 2003. [33]

Other non-IOERT mobile units have been developed as well. In 1998, a technique called TARGIT (targeted intraoperative radio therapy) was designed at the University College London for treating the tumor bed after wide local excision (lumpectomy) of breast cancer. TARGIT uses a miniature and mobile X-ray source that emits low energy X-ray radiation (max. 50 kV) in isotropic distribution. [34] (IO)-brachytherapy with MammoSite is also used to treat breast cancer. [35]

Interest in this treatment technique is growing, due in part to the development of LINAC for IOERT by factories. [36] [37] [38] [39] [40] [41] [42] [43]

See also

Related Research Articles

<span class="mw-page-title-main">Radiation therapy</span> Therapy using ionizing radiation, usually to treat cancer

Radiation therapy or radiotherapy is a treatment using ionizing radiation, generally provided as part of cancer therapy to either kill or control the growth of malignant cells. It is normally delivered by a linear particle accelerator. Radiation therapy may be curative in a number of types of cancer if they are localized to one area of the body, and have not spread to other parts. It may also be used as part of adjuvant therapy, to prevent tumor recurrence after surgery to remove a primary malignant tumor. Radiation therapy is synergistic with chemotherapy, and has been used before, during, and after chemotherapy in susceptible cancers. The subspecialty of oncology concerned with radiotherapy is called radiation oncology. A physician who practices in this subspecialty is a radiation oncologist.

<span class="mw-page-title-main">External beam radiotherapy</span> Treatment of cancer with ionized radiation

External beam radiation therapy (EBRT) is a form of radiotherapy that utilizes a high-energy collimated beam of ionizing radiation, from a source outside the body, to target and kill cancer cells. A radiotherapy beam is composed of particles which travel in a consistent direction; each radiotherapy beam consists of one type of particle intended for use in treatment, though most beams contain some contamination by other particle types.

<span class="mw-page-title-main">Brachytherapy</span> Type of radiation therapy

Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachy is Greek for short. Brachytherapy is commonly used as an effective treatment for cervical, prostate, breast, esophageal and skin cancer and can also be used to treat tumours in many other body sites. Treatment results have demonstrated that the cancer-cure rates of brachytherapy are either comparable to surgery and external beam radiotherapy (EBRT) or are improved when used in combination with these techniques. Brachytherapy can be used alone or in combination with other therapies such as surgery, EBRT and chemotherapy.

<span class="mw-page-title-main">Proton therapy</span> Medical Procedure

In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.

<span class="mw-page-title-main">Radiosurgery</span> Surgical Specialty

Radiosurgery is surgery using radiation, that is, the destruction of precisely selected areas of tissue using ionizing radiation rather than excision with a blade. Like other forms of radiation therapy, it is usually used to treat cancer. Radiosurgery was originally defined by the Swedish neurosurgeon Lars Leksell as "a single high dose fraction of radiation, stereotactically directed to an intracranial region of interest".

Adjuvant therapy, also known as adjunct therapy, adjuvant care, or augmentation therapy, is a therapy that is given in addition to the primary or initial therapy to maximize its effectiveness. The surgeries and complex treatment regimens used in cancer therapy have led the term to be used mainly to describe adjuvant cancer treatments. An example of such adjuvant therapy is the additional treatment usually given after surgery where all detectable disease has been removed, but where there remains a statistical risk of relapse due to the presence of undetected disease. If known disease is left behind following surgery, then further treatment is not technically adjuvant.

<span class="mw-page-title-main">Anaplastic thyroid cancer</span> Most aggressive form of thyroid cancer

Anaplastic thyroid cancer (ATC), also known as anaplastic thyroid carcinoma, is an aggressive form of thyroid cancer characterized by uncontrolled growth of cells in the thyroid gland. This form of cancer generally carries a very poor prognosis due to its aggressive behavior and resistance to cancer treatments. The cells of anaplastic thyroid cancer are highly abnormal and usually no longer resemble the original thyroid cells and have poor differentiation.

<span class="mw-page-title-main">Fast neutron therapy</span>

Fast neutron therapy utilizes high energy neutrons typically between 50 and 70 MeV to treat cancer. Most fast neutron therapy beams are produced by reactors, cyclotrons (d+Be) and linear accelerators. Neutron therapy is currently available in Germany, Russia, South Africa and the United States. In the United States, one treatment center is operational, in Seattle, Washington. The Seattle center uses a cyclotron which produces a proton beam impinging upon a beryllium target.

Electron therapy or electron beam therapy (EBT) is a kind of external beam radiotherapy where electrons are directed to a tumor site for medical treatment of cancer.

<span class="mw-page-title-main">Tomotherapy</span> Type of radiation therapy

Tomotherapy is a type of radiation therapy treatment machine. In tomotherapy a thin radiation beam is modulated as it rotates around the patient, while they are moved through the bore of the machine. The name comes from the use of a strip-shaped beam, so that only one “slice” of the target is exposed at any one time by the radiation. The external appearance of the system and movement of the radiation source and patient can be considered analogous to a CT scanner, which uses lower doses of radiation for imaging. Like a conventional machine used for X-ray external beam radiotherapy, a linear accelerator generates the radiation beam, but the external appearance of the machine, the patient positioning, and treatment delivery is different. Conventional linacs do not work on a slice-by-slice basis but typically have a large area beam which can also be resized and modulated.

Intraoperative radiation therapy (IORT) is radiation therapy that is administered during surgery directly in the operating room.

Particle therapy is a form of external beam radiotherapy using beams of energetic neutrons, protons, or other heavier positive ions for cancer treatment. The most common type of particle therapy as of August 2021 is proton therapy.

Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy and systemic treatment. Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes.

Stereotactic radiation therapy (SRT), also called stereotactic external-beam radiation therapy and stereotaxic radiation therapy, is a type of external radiation therapy that uses special equipment to position the patient and precisely deliver radiation to a tumor. The total dose of radiation is divided into several smaller doses given over several days. Stereotactic radiation therapy is used to treat brain tumors and other brain disorders. It is also being studied in the treatment of other types of cancer, such as lung cancer. What differentiates Stereotactic from conventional radiotherapy is the precision with which it is delivered. There are multiple systems available, some of which use specially designed frames which physically attach to the patient's skull while newer more advanced techniques use thermoplastic masks and highly accurate imaging systems to locate the patient. The result is the delivery of high doses of radiation with sub-millimetre accuracy.

<span class="mw-page-title-main">Targeted intra-operative radiotherapy</span> Method of targeted radiotherapy after surgical removal of tumours

Targeted intra-operative radiotherapy, also known as targeted IORT, is a technique of giving radiotherapy to the tissues surrounding a cancer after its surgical removal, a form of intraoperative radiation therapy. The technique was designed in 1998 at the University College London.

<span class="mw-page-title-main">Nanobiotix</span> French healthcare company

Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.

<span class="mw-page-title-main">Neutron capture therapy of cancer</span> Nonsurgical therapeutic modality for treating locally invasive malignant tumors

Neutron capture therapy (NCT) is a type of radiotherapy for treating locally invasive malignant tumors such as primary brain tumors, recurrent cancers of the head and neck region, and cutaneous and extracutaneous melanomas. It is a two-step process: first, the patient is injected with a tumor-localizing drug containing the stable isotope boron-10 (10B), which has a high propensity to capture low energy "thermal" neutrons. The neutron cross section of 10B is 1,000 times more than that of other elements, such as nitrogen, hydrogen, or oxygen, that occur in tissue. In the second step, the patient is radiated with epithermal neutrons, the sources of which in the past have been nuclear reactors and now are accelerators that produce higher energy epithermal neutrons. After losing energy as they penetrate tissue, the resultant low energy "thermal" neutrons are captured by the 10B atoms. The resulting decay reaction yields high-energy alpha particles that kill the cancer cells that have taken up enough 10B.

<span class="mw-page-title-main">Abscopal effect</span> Hypothesis in the treatment of metastatic cancer

The abscopal effect is a hypothesis in the treatment of metastatic cancer whereby shrinkage of untreated tumors occurs concurrently with shrinkage of tumors within the scope of the localized treatment. R.H. Mole proposed the term "abscopal" in 1953 to refer to effects of ionizing radiation "at a distance from the irradiated volume but within the same organism".

Prophylactic cranial irradiation (PCI) is a technique used to combat the occurrence of metastasis to the brain in highly aggressive cancers that commonly metastasize to brain, most notably small-cell lung cancer. Radiation therapy is commonly used to treat known tumor occurrence in the brain, either with highly precise stereotactic radiation or therapeutic cranial irradiation. By contrast, PCI is intended as preemptive treatment in patients with no known current intracranial tumor, but with high likelihood for harboring occult microscopic disease and eventual occurrence. For small-cell lung cancer with limited and select cases of extensive disease, PCI has shown to reduce recurrence of brain metastases and improve overall survival in complete remission.

<span class="mw-page-title-main">Jayant S. Vaidya</span> British-Indian surgeon and oncologist

Jayant S. Vaidya is a British-Indian surgeon-oncologist and clinical academic who, together with Michael Baum and Jeffrey Tobias, developed the technique called targeted intra-operative radiotherapy (TARGIT). He is a professor of surgery and oncology at the University College London, London and the author of two books on breast cancer, one on tobacco eradication, and over 200 academic articles.

References

  1. ↑ Intraoperative Irradiation. Techniques and Results. by: L. L.Gunderson, C. G. Wilett, L. B. Harrison and F. A. Calvo.Springer-Verlag 1999.
  2. ↑ Calvo FA, et al, . Intraoperative radiation therapy. In: Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK, eds. Principles and Practice of Radiation Oncology, Lippincott 2004; 4th Ed 428-56.
  3. ↑ Sutton, Elizabeth J., Tong, Ricky T et al, "Decreased aortic growth and middle aortic syndrome in patients with neuroblastoma after radiation therapy." Pediatr Radiol;39(11):1194-1202.2009
  4. ↑ [October 14–16, 2010, 6th International Conference of the International Society of Intraoperative Radiation Therapy (ISIORT) in Scottsdale, Arizona "Home Page". Archived from the original on 2010-06-26. Retrieved 2010-02-26.(ISIORT)
  5. ↑ Veronesi U, Orecchia R, Patrick Maisonneuve p, et al. “Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial”.]“Lancet Oncol. “ 2013 Dec;14(13):1269-77. doi: 10.1016/S1470-2045(13)70497-2. Epub 2013 Nov 11.
  6. ↑ Gunderson LL, Willett CG, Calvo FA, Harrison LB, eds. Intraoperative Irradiation: Techniques and Results. Second edition. New York: NY; Humana Press, 2011:189.
  7. ↑ Maluta S1, Dall'Oglio S, Marciai N, et al. Accelerated partial breast irradiation using only intraoperative electron radiation therapy in early stage breast cancer. J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e145-52. doi: 10.1016/j.ijrobp.2012.03.013. Epub 2012 Apr 28.
  8. ↑ Haddock MG1, Miller RC, Nelson H. Combined modality therapy including intraoperative electron irradiation for locally recurrent colorectal cancer. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):143-50. doi: 10.1016/j.ijrobp.2009.10.046. Epub 2010 Apr 13.
  9. ↑ Barney BM, Petersen IA, Dowdy SC, Bakkum-Gamez JN, Klein KA, Haddock MG. “Intraoperative Electron Beam Radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer. Radiat Oncol. 2013 Apr 8;8:80. doi: 10.1186/1748-717X-8-80.
  10. ↑ Marucci L, Pichi B, Iaccarino G, et al. “Intraoperative radiation therapy as an “early boost” in locally advanced head and neck cancer: Preliminary results of a feasibility study” Head & Neck' 2008;30(6):701-708.
  11. ↑ Zeidan YH1, Shiue K, Weed D, Johnstone PA, et al, Intraoperative radiotherapy for parotid cancer: a single-institution experience. Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1831-6. doi: 10.1016/j.ijrobp.2011.02.033. Epub 2011 Apr 20.
  12. ↑ Gunderson LL, Willett CG, Calvo FA, Harrison LB, eds. Intraoperative Irradiation: Techniques and Results. Second edition. New York: NY; Humana Press, 2011:249.
  13. ↑ Cai S1, Hong TS, Goldberg SI, et al.Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013 Dec 1;119(23):4196-204. doi: 10.1002/cncr.28329. Epub 2013 Sep 4.
  14. ↑ Miller ED, Xu-Welliver M, Haglund KE. “The role of modern radiation therapy in the management of extremity sarcomas.” Journal of Surgical Oncology. 2015;111:599-603. doi : 10.1002/jso.23823. Accessed 2016-11-07.
  15. ↑ Tinkle CL, Weinberg V, Braunstein SE, et al. “Intraoperative Radiotherapy in the Management of Locally Recurrent Extremity Soft Tissue Sarcoma.” Sarcoma 2015 9;2015:913565. Epub 2015 Aug 9. doi : 10.1155/2015/913565. Accessed 2016-11-07.
  16. ↑ Comas C., Prio A. Irradiation roentgen intra-abdominale, après intervention chirurgicale dans un cas de cancer de l’uterus, Congres International d’Electrologie.Imprenta Francesca Badia, Barcelona, pp 5-14, 1907
  17. ↑ Beck C.On external roentgen treatment of internal structures (eventration treatment). New York Medical Journal, Volumen LXXXIX No. 13: 621-622, 1909.
  18. ↑ Abe M. History of Intraoperative radiation therapy. In:Debelbower RR, Abe M (eds) Intraoperative radiation therapy. CRC, Boca Raton; :1-10, 1989.
  19. ↑ Gunderson LL, Willett CG, Calvo FA, Harrison LB, eds. Intraoperative Irradiation: Techniques and Results. Second edition. New York: NY; Humana Press, 2011:11.
  20. ↑ M.Abe, M.Takahashi, Intraoperative Radiotherapy: the Japanese Experience. Int.J. Radiat.Oncol.Biol. Phys. 7:863-868; 1981.
  21. ↑ Goldson A., Past, present and prospects of intraoperative radiotherapy (IOR). Semin Oncol 1981.
  22. ↑ Shipley WU, Wood WC, Tepper JE, et al. Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg pp 289-295,1984.
  23. ↑ Kinsella T, J, Peter Johnstone P., Sindelar W.F.: Intraoperative radiotherapy - Current status, International Journal of Radiation Oncology * Biology * Physics 1993 (Vol. 27Supplement 1, Page 116),1993.
  24. ↑ Fraass B.A. et al, Intraoperative radiation therapy at the National Cancer Institute: Technical innovations and dosimetry, International Journal of Radiation Oncology * Biology * PhysicsVolume 11, Issue 7, Pages 1299-1311,1985
  25. ↑ Kinsella Tj, William F. Sindelar, WF, et al : Tolerance of peripheral nerve to intraoperative radiotherapy (IORT): Clinical and experimental studies. International Journal of Radiation Oncology * Biology * Physics Volume 11, Issue 9, Pages 1579-1585, 1985
  26. ↑ Garton GR, Intraoperative radiation therapy in gynecologic cancer: the Mayo Clinic experience Gynecol Oncol. 48(3):328-32. 1993
  27. ↑ Sentenac I. et al.: The L. Intra Operative Device. : description of an original system in abstracts of IInd International Symposium on intraoperative radiation therapy, Innsbruck, September 11–14, 1988.
  28. ↑ Cattaneo G.M., Calandrino R. et al : A Modified IORT, Procedure: dosimetric results; in abstracts of IInd International Symposium on intraoperative radiation therapy, Innsbruck, September 11–14, 1988.
  29. ↑ Radiation Therapy Intraoperative Radiation Therapy (Proceedings of the Third International Symposium on Intraoperative) edited by M. Abe and M. Takahashi; pages 129-130; Pergamon Press, 1991.
  30. ↑ Tyvin A. Rich et al : Orthovoltage intraoperative radiotherapy: a new look at an old idea International Journal of Radiation Oncology * Biology * Physics, Volume 10, Issue 10, Pages 1957-1965, October 1984.
  31. 1 2 Gunderson LL, Willett CG, Calvo FA, Harrison LB, eds. Intraoperative Irradiation: Techniques and Results. Second edition. New York: NY; Humana Press, 2011:51.
  32. ↑ Gunderson LL, Willett CG, Calvo FA, Harrison LB, eds. Intraoperative Irradiation: Techniques and Results. Second edition. New York: NY; Humana Press, 2011:107.
  33. ↑ Gunderson LL, Willett CG, Calvo FA, Harrison LB, eds. Intraoperative Irradiation: Techniques and Results. Second edition. New York: NY; Humana Press, 2011:55.
  34. ↑ Jayant S Vaidya, et al. Intraoperative radiotherapy for breast cancer, Lancet Oncol,5 (3): 165–73, 2004
  35. ↑ Timothy M. Pawlik et al Potential applicability of balloon catheter–based accelerated partial breast irradiation after conservative surgery for breast carcinoma, Cancer,100, (3), 490–498, 2004
  36. ↑ Intraoperative radiotherapy (with robotic shaping and dosing). Abstracts book of 8th International Meeting of the Society of Minimally Invasive Therapy, September,18-20 1996 Cernobbio, Italy.
  37. ↑ Intraoperative Radiation Therapy in the Treatment of Cancer, Proceedings of 6th International IORT Symposium and 31st San Francisco Cancer Symposium, San Francisco, Calif., September 22–25, 1996. Frontiers of Radiation Therapy and Oncology vol 31. Editor(s): Vaeth, J.M. (Mill Valley, Calif.).
  38. ↑ New techniques in electron beam intraoperative robotic radiotherapy (IOEBRT) for cancers at higt risk of locoregional recurrences. Cancer detection and prevention, vol.20, / Issue 5, Novel Therapies I. 1996. Abstracts of Cancer detection and prevention Meeting October 26–28, 1996, Nice, France.
  39. ↑ Veronesi U., Roberto OrecchiaR., et al. Full-Dose Intraoperative Radiotherapy With Electrons During Breast-Conserving Surgery Ann. Surg., 242(1): 101–106. 2005.
  40. ↑ G Loi et al.Neutron production from a mobile linear accelerator operating in electron mode for intraoperative radiation therapy. Phys. Med. Biol.; 51(3):695-702.2006.
  41. ↑ Donald A. Goer, EBRT and IOERT: A Winning Combination, Radiology Today, Vol. 9, No. 7, P. 29. 2008.
  42. ↑ Soriani A, Felici G, Fantini M et al. Radiation protection measurements around a 12 MeV mobile dedicated IORT accelerator. Med Phys.; 37(3):995 1003. 2010.
  43. ↑ Skandarajah AR, Lynch AC, Mackay JR, Ngan S, Heriot AG (March 2009). "The role of intraoperative radiotherapy in solid tumors." Ann. Surg. Oncol. 16 (3): 735–44
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.